The difference is hours, not days, so it primarily affects the acute post-injection experience rather than overall weekly efficacy
If approved, the earliest availability would be mid-to-late 2027
It targets GIP and GLP-1 receptors
16 GLP-1RAs achieve sustained pharmacological effects by resisting degradation by DPP-4 in the body, consequently contributing to hyperglycemia and insulin resistance related to glucose metabolism, 17,18 lipid profile alterations, changes in fat composition, visceral fat accumulation, and obesity related to lipid metabolism, 1921 which constitute the systemic metabolic characteristics of interest in MASLD management
Compared to other technologies, LC-MS/MS offers high specificity, selectivity, and a wide dynamic range, making it less susceptible to interference and applicable across various biological matrices
GLP-1s can offer an effective solution and make staying motivated on your weight loss journey easier than ever